15 news items
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price Target
CLNN
28 May 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
CLNN
28 May 24
is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function
Analyst Scoreboard: 6 Ratings For Clene
CLNN
23 May 24
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target
Benchmark Reiterates Buy on Clene, Maintains $5 Price Target
CLNN
23 May 24
Benchmark analyst Bruce Jackson reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $5 price target.
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $7 Price Target
CLNN
8 May 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.
nqi57rk65jh
CLNN
1 May 24
nanotherapeutics to treat these diseases. We target improvement of mitochondrial function via the catalytic activity of our asset, CNM-Au8, to improve
w17jc 8dwuieiczoiz1k5i1jyy38
CLNN
17 Apr 24
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.6, along
aewgnjl22a adk3d6q4jgqu68auhxresl1
CLNN
17 Apr 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.
9f9c6y2noi5tqukrbxi91beyxg1s72lkl 13umz9u2i0knximxxoadzv
CLNN
16 Apr 24
, "Observing such a profound clinical benefit with corresponding improvements in physiologic measures utilizing a mechanism that does not target immune
ce3y0cip54
CLNN
20 Mar 24
Benchmark analyst Bruce Jackson reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $5 price target.
argw e6bxl1gz0fhraz94wl2a4s6tict9gw
CLNN
19 Mar 24
all target markets, industries and demographics in the most effective manner possible; (2) article and editorial
pys5njsli1kv1a3ql79myzoilbsg0o6pg5hdzimqt6ox6smzpqqh01ieb9gp
CLNN
13 Mar 24
Analysts have set 12-month price targets for Clene, revealing an average target of $7.0, a high estimate of $7.00, and a low estimate
bo05i0pb08h4oy51e44zy i3z7cy4uthmv89iwglvl9gxi0ge38hffav
CLNN
13 Mar 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.
en5js3k1i6uq0145iry8fom2yie7x8ejr
CLNN
13 Mar 24
Announced peer-reviewed publication characterizing CNM-Au8 brain target engagement in the Journal of Nanobiotechnology
5di6a2ml8l8m2ygnacpa1m57c
CLNN
11 Mar 24
HC Wainwright & Co. analyst Joseph Pantginis maintains Clene (NASDAQ:CLNN) with a Buy and maintains $7 price target.
- Prev
- 1
- Next